GERMANTOWN, Md., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company
developing novel treatments for nervous system diseases, today announced that data from the Company’s Phase 2 study of NSI-189 in
patients with major depressive disorder will be presented at the 56th American College of Neuropsychopharmacology (ACNP)
Annual Meeting, which is being held in Palm Springs, California from December 3-7, 2017.
Poster presentation details are as follows:
Title: A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189 Phosphate, a Neurogenic Compound Among
Out-Patients with Major Depressive Disorder
Abstract Number: M79
Session Title: Poster Session I
Presenter: George Papakostas, M.D., Massachusetts General Hospital
Date and Time: Monday, December 4, 2017, 5:30 PM – 7:30 PM PT
About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of
high unmet medical need. NSI-189 is a small molecule in clinical development for major depressive disorder (MDD) and in preclinical
development for Angelman syndrome, irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes, and stroke.
NSI-566 is a stem cell therapy being tested for treatment of paralysis in stroke, chronic spinal cord injury (cSCI) and
Amyotrophic Lateral Sclerosis (ALS). Neuralstem’s diversified portfolio of product candidates is based on its proprietary neural
stem cell technology.
Cautionary Statement Regarding Forward Looking Information
This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by
words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature
address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to
differ materially from those expressed in our forward-looking statements include risks inherent in the development and
commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for
future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the
Annual Report on Form 10-K for the year ended December 31, 2016, and Form 10-Q for the three and nine months ended September 30,
2017, filed with the Securities and Exchange Commission (SEC), and in other reports filed with the SEC. We do not assume any
obligation to update any forward-looking statements.
Contact:
Kimberly Minarovich
Argot Partners (Investor Relations)
212-600-1902
kimberly@argotpartners.com
